

S0040-4039(96)00059-7

Chiral Acetals: Stereocontrolled Syntheses of 16-, 17-, and 18-Hydroxyeicosatetraenoic Acids, Cytochrome P-450 Arachidonate Metabolites

Bertrand Heckmann, Charles Mioskowski*

Laboratoire de Synthèse Bio-Organique, Associé au CNRS
 Université Louis Pasteur, F-67401 Illkirch, France

Sun Lumin, J.R. Falck*


Department of Molecular Genetics and Pharmacology,
 University of Texas Southwestern Medical Center,
 Dallas, Texas 75235, USA

Shouzou Wei, and Jorge H. Capdevila

Departments of Medicine and Biochemistry, Vanderbilt University
 Medical Center, Nashville, Tennessee 37232, USA


Abstract/ Chiral adducts from Grignard or allylsilane additions to 1,3-dioxan/1,3-dioxolan-4-ones were exploited for the total synthesis of the *R*- and *S*-isomers of the title eicosanoids.

Extensive investigations by these and other laboratories have established a unique paradigm for eicosanoid biosynthesis via cytochrome P-450.¹ Most notably, the profile of metabolites and their absolute configurations are isozyme dependent and, thus, reflect the interplay amongst such factors as pathophysiology, gender, species, tissue, age, diet, and xenobiotic induction.² This often results in complex mixtures of closely related metabolites as recently observed³ in the ω -oxidation pathway from which 16-,17-, and 18-hydroxyeicosatetraenoic acid (16-,17-,18-OH-AA) were isolated (eq 1). To expedite current stereochemical studies and pharmacological evaluations of this pathway, we describe herein the enantiospecific total syntheses of the three monooxygenase metabolites 1-3 by the strategic exploitation of chiral acetals.⁴



Scheme 1 summarizes the route to 16-OH-AA. Nucleophilic S_N2 addition⁵ of butyl magnesium bromide in Et₂O to the acetalic center of homochiral 1,3-dioxolan-4-one **4**,⁶ prepared from 3-methyl-2-butenal and (*R*)-mandelic acid, followed by esterification with diazomethane readily afforded substituted O-allyl mandelate **5**.⁷ Diisopropyl acetal **6** was obtained from **5** via low temperature ozonolysis with Me₂S workup and incubation of the resultant crude aldehyde with triisopropyl orthoformate in the presence of catalytic pyridinium *p*-toluenesulfonate (PPTS). Mild oxidative decarboxylation of **6** via an *in situ* generated dioxetanone as described by Heckmann et al.⁸ led to the corresponding benzoate. Minor amounts of free alcohol released during this process were benzoylated and the combined degradation product was hydrolyzed using trifluoroacetic acid to furnish aldehyde **7**. Wittig condensation of **7** with 13-carbomethoxytrideca-3(*Z*),6(*Z*),9(*Z*)-trien-1-ylidene-triphenylphosphorane^{3a} (**9**) and methanolysis of the benzoate gave rise to methyl 16(*S*)-OH-AA(**8**), [α]_D²³ = -5.4 (c 0.7, acetone).⁹ Mitsunobu inversion¹⁰ (PhCO₂H, Ph₃P, DEAD) of **8** and benzoate removal (NaOMe, MeOH, 24°C, 2h) yielded the 16(*R*)-isomer in 65-70% overall yield.

Scheme 1




^a*n*-BuMgBr, Et₂O, -78→24°C, 12h; CH₂N₂. ^bO₃, MeOH, -78°C; Me₂S. ^c(*i*PrO)₃CH, PPTS, Et₂O, 12h.

^d*t*-BuOK, THF, O₂, 24°C, 10 min; PhCOCl, py. ^eCF₃CO₂H, CH₂Cl₂, 24°C, 10 min. ^f**9**, NaN(TMS)₂, THF/HMPA (5:1), -78°C, 1h. ^gNaOMe, MeOH, 24°C, 10h.

An analogous strategy utilizing **10**, the adduct¹¹ of (*R*)-mandelic acid with 5-methyl-4-hexenal, led to both antipodes of **3** (Scheme 2). In this instance, however, sequential copper catalyzed addition⁵ of ethyl magnesium bromide to **10** and diazomethane esterification evolved **11** as a chromatographically separable [SiO₂:Et₂O/hexane(1:9)] diastereomeric mixture (92:8). Ozonolytic cleavage of the trisubstituted olefin and condensation of the product with propanedithiol gave rise to **12** which was converted to aldehyde **13** by oxidative degradation of the chiral auxiliary as described above and silver assisted thioacetal hydrolysis. Reaction of **13** with ylide **9** and methanolysis of the benzoate protecting group yielded methyl 18(*S*)-OH-AA (**14**), [α]_D²³ = +4 (c 0.35, acetone). As above, the *R*-isomer was secured without complication by Mitsunobu inversion.


Scheme 2



^aEtMgBr, CuI, Et₂O, -20°C, 12h; CH₂N₂. ^bO₃, MeOH, -78°C; Me₂S. ^cHSC₂H₄SH, BF₃·Et₂O, Et₂O, -20→24°C, 24h. ^d*t*-BuOK, THF, O₂, 24°C, 10 min; PhCOCl, py. ^eAgNO₃, NCS, CH₃CN/H₂O, 24°C, 10 min. ^f9, NaN(TMS)₂, THF/HMPA (5:1), -78°C, 30 min. ^gNaOMe, MeOH, 24°C, 10h.

The six-membered 1,3-dioxan-4-one **15**, from butanal and 3(*R*)-hydroxybutyric acid,¹² reacted with allyltrimethylsilane in presence of isopropoxytitanium trichloride to form the ether **16** (Scheme 3). Olefination with ylide **9** of the aldehyde from ozonolysis of **16** afforded diester **17**. Based induced β-elimination of the chiral auxiliary liberated methyl 17(*R*)-OH-AA (**18**), [α]_D²⁴ = +4 (c 1.4, acetone).⁴ Transposition to the *S*-isomer relied on the standard Mitsunobu protocol.

Scheme 3



^aTMSCH₂CH=CH₂, *i*-PrOTiCl₃, CH₂Cl₂, -78°C; CH₂N₂. ^bO₃, MeOH, -78°C; Me₂S. ^c9, NaN(TMS)₂, THF/HMPA (5:1), -78°C, 0.5h. ^d*t*-BuOK, THF, 0°C, 10 min.

Saponification of **8**, **14**, **18**, and their enantiomers provided the corresponding free acids which were identical by HPLC and GC/MS (as pentafluorobenzyl ester trimethylsilyl ethers) with their respective enzymatically derived counterparts.⁴ These metabolites have been identified as endogenous constituents of kidney, aorta, and intestines where they display regio- and stereodependent vascular effects.¹³ Details of current *in vivo* stereochemical studies of **1-3** and their physiological role have been reported elsewhere.¹⁴

Acknowledgment: Financial support was provided by NIH (DK-38226), CNRS, and the Robert A. Welch Foundation (I-782). Funds for the purchase of a mass spectrometer were provided by NIH (S10 RR05922).

References and Notes

1. Capdevila, J.H.; Falck, J.R.; Estabrook, R.W. *FASEB J.* **1992**, *6*, 731-736.
2. Capdevila, J.H.; Karara, A.; Waxman, D.J.; Martin, M.V.; Falck, J.R.; Guengerich, F.P. *J. Biol. Chem.* **1990**, *265*, 10865-10871.
3. (a) Falck, J.R.; Lumin, Sun; Blair, I.; Dishman, E.; Martin, M.V.; Waxman, D.J.; Guengerich, F.P.; Capdevila, J.H. *J. Biol. Chem.* **1990**, *265*, 10244-10249. (b) Clare, R.A.; Huang, S.; Doig, M.V.; Gibson, G.G. *J. Chromatography* **1991**, *562*, 237-247. (c) Oliw, E. *J. Biol. Chem.* **1989**, *264*, 17845-17853.
4. Chemical syntheses of 17- and 18-OH-AA: Falck, J.R.; Lumin, Sun; Lee, S.-G.; Heckmann, B.; Mioskowski, C.; Karara, A.; Capdevila, J. *Tetrahedron Lett.* **1992**, *33*, 4893-4896. Also see ref. 3a.
5. Heckmann, B.; Mioskowski, C.; Yu, J.; Falck, J.R. *Tetrahedron Lett.* **1992**, *33*, 5201-5204.
6. B. Heckmann, C. Mioskowski, Rama K. Bhatt, J.R. Falck *Tetrahedron Lett.* preceding paper.
7. Satisfactory spectral data and/or elemental analyses were obtained for all new compounds using chromatographically homogeneous samples.
8. Heckmann, B.; Alayrac, C.; Mioskowski, C.; Chandrasekhar, S.; Falck, J.R. *Tetrahedron Lett.* **1992**, *33*, 5205-5208.
9. Physical data for **4**: ¹H NMR (200 MHz, CDCl₃) δ 1.87 (m, 6H), 5.26 (d, J=1.2Hz, 1H), 5.44 (m, 1H), 6.32 (dd, J=7.8, 1.2Hz, 1H), 7.35-7.51 (m, 5H); mp 77-81°C (EtOAc/hexane); Anal. Calcd for C₁₃H₁₄O₃: C, 71.54, H, 6.47. Found C, 71.38, H, 6.68. **8**: ¹H NMR (200 MHz, C₆D₆) δ 0.87 (t, J=6.8Hz, 3H), 1.15-1.70 (m, 8H), 1.90-2.15 (m, 4H), 2.65-2.95 (m, 6H), 3.33 (s, 3H), 4.38 (dd, J=7.14Hz, 1H), 5.22-5.60 (m, 8H); TLC(SiO₂) EtOAc/hexane(1:2), R_f~0.39. **10**: ¹H NMR (200 MHz, CDCl₃) δ 1.56 (s, 3H), 1.73 (s, 3H), 1.97 (m, 2H), 2.25 (m, 2H), 5.16 (tq, J=7.5, 1.0Hz, 1H), 5.25 (d, J=1.2Hz, 1H), 5.7 (td, J=5.1Hz, 1H), 7.3-7.5 (m, 5H); ¹³C NMR (50 MHz, CDCl₃) δ 17.66, 21.63, 25.64, 34.31, 76.70, 104.22, 122.17, 126.81, 128.72, 129.14, 133.34, 172.62; mp. 44-46°C; [α]_D=-68 (c 1.8, CHCl₃). **15**: ¹H NMR (200 MHz, CDCl₃) δ 0.88 (t, J=7.2Hz, 3H), 1.22 (d, J=8.4Hz, 3H), 1.44 (m, 2H), 1.67 (m, 2H), 2.42 (ABX, δ_a=2.59, δ_b=2.29, J_{ab}=17.8, J_{ax}=4.4, J_{bx}=10.7Hz, 2H), 3.95 (m, 1H), 5.25 (t, J=4.9Hz, 1H); ¹³C NMR (50 Mhz, CDCl₃) δ 13.51, 16.23, 20.97, 36.52, 37.49, 70.38, 103.02, 167.67. Esters **14** and **18** were identical with previously prepared standards.⁴
10. Mitsunobu, O. *Synthesis* **1981**, 1-28.
11. Marbet, R.; Saucy, G. *Helv. Chim. Acta.* **1967**, *50*, 2095-2100.
12. Seebach, D.; Imwinkelried, R.; Stucky, G. *Angew. Chem. Int. Ed. Engl.* **1986**, *25*, 178-180.
13. Prof. Mairead Carroll (New York Medical College, Valhalla, NY), personal communication.
14. Laethem, R.M.; Balazy, M.; Falck, J.R.; Laethem, C.L.; Koop, D.R. *J. Biol. Chem.* **1993**, *268*, 12912-12918.

(Received in France 22 September 1995; accepted 5 January 1996)